For research use only. Not for use in humans.

Anti-Mesothelin (BMS-986148)

Synonyms: MSLN, CAK1

Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD.

Anti-Mesothelin (BMS-986148)

Quality Control

Batch: A300201 Purity: 99% Protein concentration: 7.38mg/ml Endotoxin Level: <1EU/mg
99

Mechanism of Action

Description
Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD.
References

Product Details

Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06885697 RECRUITING Drug: cyclophosphamide|Drug: fludarabine Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms National Cancer Institute (NCI) 2025-07-08 PHASE1
NCT07010523 RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Malignant Solid Tumors First Affiliated Hospital of Zhejiang University 2024-10-15
NCT05848999 UNKNOWN Mesothelin-positive Advanced Malignant Solid Tumors Zhejiang University 2023-04-27 PHASE1
NCT05531708 WITHDRAWN Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Refractory Solid Tumors Shanghai Pudong Hospital 2021-04-02 PHASE1
NCT05783089 NOT_YET_RECRUITING Mesothelin-positive Advanced Malignant Solid Tumors Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2023-04 PHASE1
NCT05775666 UNKNOWN Solid Tumor Peking University 2023-03 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.